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of novel compounds. These systems contain a set ofNew Start and Finish
enzymes or modules for every cycle of chain extension,for Complex Polyketide as well as a loading module for transferring the starter
acyl group onto the first KS domain. This modular orga-Biosynthesis
nization allows programmed assembly of a defined se-
quence of starter and extender units, together with con-
trolled processing of each -ketone group. The final
The polyketide vicenistatin has significant anticancer product may be cyclized by a thioesterase (TE) to give
activity. In the January issue of Chemistry & Biology, a macrolactone.
Kakinuma and coworkers [20] reported on the viceni- Starter units may derive from acyl CoAs that are re-
statin biosynthetic gene cluster and demonstrated in cruited from primary metabolism and used directly. Ace-
vitro glycosylation of its aglycone core, raising the tyl and propionyl starters can also be generated by de-
possibility of producing analogs with altered sugar carboxylation of malonyl and methylmalonyl groups
residues. attached to loading module ACPs. Other more unusual
organic acids are activated as acyl adenylates before
The polyketide group of natural products includes nu- transfer to CoA or an ACP [3]. Modular PKSs generally
merous antibiotics, anticancer drugs, and immunosup- use malonyl and methylmalonyl-CoA as extender units.
pressants. Biosynthesis of these important compounds Ethylmalonyl and methoxymalonyl units are used less
involves assembly of carbon chains from small acyl pre- frequently [4]. The sequences of malonyl and methylmal-
cursors. In general, chain elongation is catalyzed by onyl-specific AT domains can be distinguished by char-
a set of enzymes that together make up a polyketide acteristic motifs. A separate region of the AT domain
synthase (PKS). A starter or growing acyl chain migrates contains critical residues that appear to determine sub-
onto the active site cysteine of a ketosynthase (KS), strate specificity. Methylmalonate-specific AT domains
and an acyltransferase (AT) loads a dicarboxylic acyl use only the (2S) isomer of methylmalonyl CoA [5]. When
extender unit onto the phosphopantetheine thiol of an this branched extender is used, condensation occurs
acyl carrier protein (ACP). A decarboxylative Claisen with inversion of stereochemistry at C-2 so that a (2R)
condensation leaves an extended -ketoacyl chain 2-methyl-3-ketoacyl chain is generated initially [6]. With
attached to the ACP [1]. A complete chain extension some modules epimerization must occur to give the final
cycle can involve three more steps: conversion of the alkyl stereochemistry. Exactly how this epimerization is
-ketone group to an alcohol by a ketoreductase (KR), achieved is still unclear. The epimerase activity seems
dehydration by a dehydratase (DH) to form a trans - to reside within the KS domain [7], but there are no
unsaturated acyl intermediate, and finally reduction by obvious differences between the primary sequences of
an enoyl reductase (ER) to give a saturated chain. The epimerizing and nonepimerizing KSs.
condensations between acyl thioesters may be re- KR domains are responsible for determining the final
peated many times, but PKSs rarely take -ketone pro- stereochemistry at chiral centers derived from reduction
cessing all the way to the third stage. As a result, ke- of -ketones to alcohols [8]. Conserved amino acid resi-
tones, hydroxyl groups, and double bonds appear at dues at a few key positions appear to be useful for
defined positions within polyketide chains. predicting KR stereospecificity [9, 10]. Predictive meth-
Chemical and genetic studies have now uncovered ods suggest that the DH domains of modular PKSs nor-
many different types of PKS [2]. Of these, the modular mally act on (3R)-hydroxyacyl chains to give trans dou-
ble bonds. Few complex polyketides have cis doublePKSs are the most amenable to redesign for production
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bonds, and it is still unclear how these are introduced. ies will be required to investigate further the origin of this
intriguing starter unit. Whereas many PKSs epimerizeER domains occur relatively infrequently in PKS mod-
ules and are so far the least studied of all of the constit- chiral centers derived from C-2 of a branched extender
unit, the vicenistatin-synthesizing system is unusual inuent domains. These domains must determine alkyl ste-
reochemistry when incorporation of a branched extender epimerizing the primer.
The vicenistatin PKS contains eight extension mod-is followed by complete reduction of the -ketone.
Numerous modular PKSs have now been investigated ules contained within four multienzyme polypeptides.
The first extension module is preceded by an unusualand considerable progress has been made in engi-
neering these systems to make new macrolactones loading module that contains only an ACP domain. It is
unclear exactly how the final starter unit is transferred[1, 11]. Polyketide structures can be modified further,
notably by glycosylation with various deoxyhexoses from a discrete ACP to the loading module. Vicenistatin
also has a double bond that cannot result from straight-and aminodeoxyhexoses [11–13]. Alteration of these
sugar moieties can dramatically alter biological activity forward extension of an - unsaturated intermediate.
The position of this bond could be accounted for by an[13, 14]. Glycosylation engineering is therefore an area of
considerable interest for developing novel therapeutics. isomerization to give a trans - double bond prior to
further chain elongation. Other possible explanationsStudies on the biosynthesis of other complex polyke-
tides could allow novel modifications of macrolactone include double bond migration after closure of the mac-
rolactam ring. An understanding of this process couldrings, and further diversification of carbohydrate moie-
ties. The group led by Kakinuma has investigated the lead to a new means of diversifying engineered polyke-
tide structures.biosynthesis of vicenistatin, an antitumor compound
produced by Streptomyces halstedii HC34 [15–18]. Vi- The cluster also encodes the five enzymes necessary
for formation of dTDP-D-vicenisamine from glucose-1-cenistatin is a 20-membered macrolactam ring to which
a novel aminodeoxysugar, vicenisamine, is attached. A phosphate. The previous identification of vicenistatin M
[15] indicates that the VinC glycosyltransferase showsminor cometabolite, vicenistatin M, contains the neutral
sugar D-mycarose in place of vicenisamine [15]. Viceni- some sugar flexibility and can transfer D-mycarose as
well as vicenisamine onto the aglycone core. Initial hy-statin M is not cytotoxic and has no antitumor activity.
Chemical feeding with labeled precursors indicates bridization experiments detected two sets of genes for
NDP-hexose 4,6 DH and NDP-4-keto-6-deoxyhexosethat the vicenistatin carbon chain is assembled from ace-
tate and propionate extender units [16]. The starter is a 2,3 DH enzymes in the genome of S. halstedii. This
suggests that an entirely separate cluster of genes is3-amino-2-methylpropionyl unit that is generated by de-
carboxylation of glutamate-derived 3-methylaspartate. involved in biosynthesis of dTDP-D-mycarose. Alter-
natively, D-mycarose could result if a vicenisamine path-Surprisingly, however, labeled 3-amino-2-methylpropio-
nate is not incorporated as a starter. This suggests that way intermediate were intercepted by a C-methyl trans-
ferase and a reductase that are not encoded within the3-methylaspartate must be activated as an ACP or CoA
thioester prior to decarboxylation and transfer to the vicenistatin cluster.
No attempts to genetically manipulate the vicenistatinPKS. More detailed feeding studies revealed that (2S,
3S)-3-methylaspartate is converted to a starter and in- producer have yet been reported. However, the viceni-
statin glycosyltransferase was overproduced in Esche-corporated whereas the (2S, 3R)-isomer is not [17]. This
indicates that after conversion to a thioester, the acyl richia coli and was shown to modify the purified agly-
cone with vicenisamine. It should therefore be possiblechain undergoes epimerization, as well as decarboxyl-
ation, to generate the (2R)-3-amino-2-methylpropionyl to carry out in vitro glycosylation with alternative amino-
deoxyhexoses so as to produce new vicenistatin ana-group that would give the final stereochemistry ob-
served in vicenistatin [18]. logs. This would reduce the need to carry out numerous
gene replacements. In addition, there has been signifi-In the January issue of Chemistry & Biology, Kakinuma
and colleagues published an extension of their chemical cant recent progress in expanding the repertoire of
dTDP-deoxysugars that can be generated by enzymaticstudies by analyzing the vicenistatin biosynthetic genes.
The cluster encodes a B12-dependent mutase that re- synthesis in vitro [19]. These advances could lead to the
development of improved vicenistatin-based anticancerarranges glutamate to (2S, 3S)-3-methylaspartate. Two
enzymes appear to be capable of activating this starter agents.
amino acid to an acyl adenylate. One of these has a
CoA ligase domain and may attach the starter to CoA or
Patrick Caffrey
to a discrete ACP as a thioester. A pyridoxal phosphate
Centre for Synthesis and Chemical Biology
(PLP)-dependent amino acid decarboxylase is likely to
Department of Industrial Microbiology
generate the 3-amino-2-methylpropionyl group. There
Conway Institute of Biomolecular and
is no candidate epimerase gene within the cluster. The
Biomedical Researchdecarboxylation reaction is likely to involve condensa-
University College Dublintion of the PLP aldehyde group with the amino group
Dublin 4of the activated 3-methylaspartyl thioester. Decarboxyl-
Irelandation would position the methyl-branched carbon atom,
now designated C-2, between the carbon atom of a
Selected Reading
protonated imine and the thioester carbonyl carbon.
This could well favor an epimerization reaction by in- 1. Staunton, J., and Weissman, K.J. (2001). Nat. Prod. Rep. 18,
380–416.creasing the acidity of the C-2 proton. Biochemical stud-
Previews
157
2. Shen, B. (2003). Curr. Opin. Chem. Biol. 7, 285–295. 12. Rix, U., Fischer, C., Remsing, L., and Rohr, J. (2002). Nat. Prod.
Rep. 19, 542–580.3. Moore, B.S., and Hertweck, C. (2002). Nat. Prod. Rep. 19, 70–99.
4. Liou, G.F., and Khosla, C. (2003). Curr. Opin. Chem. Biol. 7, 13. Mendez, C., and Salas, J. (2001). Trends Biotechnol. 19,
449–456.279–284.
5. Marsden, A.F.A., Caffrey, P., Aparicio, J.F., Loughran, M., Staun- 14. Madduri, K., Kennedy, J., Rivola, G., Inventi-Solara, A., Filippini,
S., Zanuso, G., Colombo, A.L., Gewain, K., Occi, J.L., McNeil,ton, J., and Leadlay, P.F. (1994). Science 263, 378–380.
6. Weissman, K.J., Timoney, M., Bycroft, M., Grice, P., Hanefeld, D.J., et al. (1998). Nat. Biotechnol. 16, 69–74.
15. Otsuka, M., Fujita, M., Matsushima, Y., Eguchi, T., Shindo, K.,U., Staunton, J., and Leadlay, P.F. (1997). Biochemistry 36,
13849–13855. and Kakinuma, K. (2000). Tetrahedron 56, 8281–8286.
16. Otsuka, M., Eguchi, T., Shindo, K., and Kakinuma, K. (1998).7. Holzbaur, I.E., Ranganathan, A., Thomas, I.P., Kearney, D.J.A.,
Reather, J.A., Rudd, B.A.M., Staunton, J., and Leadlay, P.F. Tetrahedron Lett. 39, 3185–3188.
17. Nishida, H., Eguchi, T., and Kakinuma, K. (2001). Tetrahedron(2001). Chem. Biol. 8, 329–340.
8. Khosla, C., Gokhale, R.S., Jacobsen, J.R., and Cane, D.E. (1999). 57, 8237–8242.
18. Arai, H., Matsushima, Y., Eguchi, T., Shindo, K., and Kakinuma,Annu. Rev. Biochem. 68, 219–253.
9. Reid, R., Piagentini, M., Rodriguez, E., Ashley, G., Viswanathan, K. (1998). Tetrahedron Lett. 39, 3181–3184.
19. Hoffmeister, D., Yang, J., Liu, L., and Thorson, J.S. (2003). Proc.N., Carney, J., Santi, D.V., Hutchinson, C.R., and McDaniel, R.
(2003). Biochemistry 42, 72–79. Natl. Acad. Sci. USA 100, 13184–13189.
20. Ogasawara, Y., Katayama, K., Minami, A., Otsuka, M., Eguchi,10. Caffrey, P. (2003). Chembiochem 4, 654–657.
11. Rawlings, B.J. (2001). Nat. Prod. Rep. 18, 231–281. T., and Kakinuma, K. (2004). Chem. Biol. 11, 79–86.
Chemistry & Biology, Vol. 11, February, 2004, 2004 Elsevier Science Ltd. All rights reserved. DOI 10.1016/j.chembiol.2004.02.004
plex then initiates transcription. The ability to selectivelyUnderstanding Diseases
bind one NR isoform to a SRC would allow the unravelingvia Receptor Regulation of individual signaling pathways for that NR and SRC
complex. There are three known SRCs: SRC1, SRC2,
and SRC3 [3–5]. They appear to play distinct but, per-
haps, partially overlapping functions [4, 6]. The NRs bindIn this issue of Chemistry & Biology, Guy and cowork-
to an area of a SRC protein known as the nuclear recep-ers [11] demonstrate that they can selectively recruit
tor-interacting domain (NID). This NID area contains mul-individual nuclear receptors by using small molecules
tiple, conserved interfaces that have identical se-(proteomimetics) in combination with specific ago-
quences specific for each SRC, which are known as NRnists. This may ultimately lead to a link between the
boxes. The NR boxes contain sequences of the motifreceptor’s signaling pathway and its role in individual
L1XXL2L3, [1, 2], where L depicts a position of diversity,diseases.
and X is an amino acid specific to that SRC. Thus, for
example, the SRC2 NR box contains multiple, conservedA number of diseases, including cancer and metabolic
interfaces within the NID that are sequence LERLL.disorders, are known to be associated with the inappro-
One series of structurally similar NRs are two isoformspriate regulation of the nuclear hormone receptor tran-
of estrogen receptors: ER and ER. Both ER and ERscription factors (NRs). [1] NRs regulate transcription
bind to SRC2 to activate transcription. However, theybased on hormone levels. The complex mechanisms
regulate entirely different gene transcription pathwaysinvolved in these signaling pathways are poorly under-
[7]. Both ER and ER bind to the second box of SRC2stood. Selectively examining each nuclear receptor’s
(SRC2-2) in the presence of a number of agonists, in-signaling pathway will provide insight into their connec-
cluding estradiol, diethyl stilbesterol, or genistein.tion to specific diseases.
In earlier work using a small molecule library of com-Uncoupling the signaling pathways of these NRs is
pounds that mimicked the second SRC2 NR box (SRC2-challenging. The ability to selectively activate one NR
2), Guy and coworkers discovered a small molecule pro-in the presence of other NRs using small molecules has
teomimetic that selectively blocked binding of ER inbeen limited by the similarity of one NR isoform over
the presence of ER to SRC2 [8]. Thus transcriptionanother and the challenge of replacing a protein-protein
regulation by ER was inhibited in the presence of ER,interaction with a small molecule-protein interaction.
while transcription regulated by ER was unaffected. InUpon discovery of lead small molecules, compound li-
addition, they found a proteomimetic that could prefer-braries targeted to individual NRs could be screened
entially inhibit the binding of ER to SRC2 in the pres-for their specificity for each NR. The discovery of unique
ence of ER. This new tool for selectively inhibiting indi-small molecule leads for each NR would offer selective
vidual NRs using a small molecule for regulating nuclearcontrol of the signaling pathways for the individual nu-
receptors is an excellent lead for the development ofclear receptor, illuminating the connection between the
small, drug-like compounds that will ultimately illumi-specific signals regulating the pathways and the disease
nate the function of these individual receptors.state.
This issue of Chemistry & Biology includes an articleNRs bind to small molecule agonists: hormones.
by Guy and coworkers that demonstrates how smallThese hormones activate the NRs, leading the NR•ago-
molecule proteomimetics can be used to selectively re-nist complex to recruit a specific steroid receptor coacti-
vator (SRC)[1, 2] (Figure 1). This NR•agonist•SRC com- cruit individual NRs that are specific to the hormone
